Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients

NCT01837277 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

186

Enrollment

OTHER

Sponsor class

Conditions

Severely Immunocompromised HIV Patients

Interventions

DRUG: Dolutegravir 50 mg
DRUG: Efavirenz-based regimens

Sponsor

Fundação Bahiana de Infectologia